Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2024-01-15 Regulatory Filings
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice informing about an upcoming Board Meeting scheduled for January 23, 2024, to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2023. It references regulatory compliance under SEBI regulations and mentions the closure of the trading window for insider trading prevention. The document does not contain any financial data or results itself but is an announcement of a future event related to financial reporting. The length is only 2310 characters, which is short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other more specific categories like Interim Report or Earnings Release, which would require actual financial data or results.
2024-01-15 English
Spurt in Volume
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the National Stock Exchange of India Limited regarding a clarification on a recent spurt in trading volume of the company's securities. It references compliance with SEBI Listing Regulations and states that no material information is pending disclosure. The document is a regulatory communication clarifying market activity and compliance, not a financial report, earnings release, or any other detailed report. It is short (2543 characters) and serves as a regulatory filing or compliance clarification. Therefore, it fits best under Regulatory Filings (RNS).
2024-01-03 English
Monitoring Agency Report
Regulatory Filings
2023-11-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call held by Glenmark Life Sciences Limited for the quarter ended September 30, 2023. It includes management commentary on financial performance, business outlook, segmental performance, and Q&A with analysts. The text explicitly mentions it is a transcript of the earnings call and contains detailed financial data such as revenue, EBITDA, PAT, margins, and segmental breakdowns. The document also references the approval of quarterly results by the board and the release of these results to stock exchanges. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls including earnings calls with Q&A. The document is not merely an announcement or summary but the full transcript, and it contains substantive financial discussion and analysis. Therefore, the correct classification is CT with high confidence.
2023-10-25 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation Q2 FY24' and is addressed to stock exchanges referencing regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, which mandates disclosure of material events including investor presentations. The content includes detailed financial performance data for Q2 FY24, including revenue, EBITDA, PAT, segment performance, market mix, and R&D capabilities. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. It contains detailed financial and business performance information typical of an investor presentation. There is no indication that this is a full annual or interim report, audit report, or earnings release. The presence of detailed slides and financial metrics aligns with the definition of an Investor Presentation (IP).
2023-10-20 English
Press Release
Interim / Quarterly Report Classification · 100% confidence The document is a press release and management discussion and analysis (MD&A) for the second quarter ended September 30, 2023. It includes detailed financial performance data such as revenue, EBITDA, PAT, segment performance, balance sheet items, and business highlights. The document references the SEBI (Listing Obligations and Disclosure Requirements) regulation 30, indicating it is a regulatory disclosure. The content includes comprehensive financial statements and management commentary for a quarterly period, which fits the definition of an Interim / Quarterly Report (IR). The document length is over 13,000 characters and contains substantive financial data and analysis, not just an announcement or summary. Therefore, it is classified as an Interim / Quarterly Report (IR). Q2 2024
2023-10-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.